Pre-IPO - Biotech

Västra Hamnen Corporate Finance acts as financial advisor to the company in connection with their Pre-IPO. 

Size of the offer: SEK 100 million
Pre-money valuation: SEK 300 million
Most recent post-money valuation: SEK ~250 million
IPO within 12 months

The Company in brief
The Company is a privately held Swedish biotech developing innovative new medicines for severe diseases with a large unmet medical need focusing on pain and cancer. The Company uses a proprietary, next-generation antibody platform that can generate antibodies against difficult targets where other technologies failed. 

Per Lönn
Vice VD

Telefon: +46 40 200 255
Mobil: +46 733 96 84 51



Västra Hamnen Corporate Finance AB | Jungmansgatan 12 | 211 11 Malmö | 040-200 250 |